Q&A: API Experts - A Small Molecule's Journey Through API Development
Developing a small molecule API is often a perilous process for new and emerging pharma companies. The primary goal, whether in early- or late-phase development, is to obtain sufficient material to support your clinical requirements. Yet the regulatory requirements for each phase are different, and they require different skill sets. Here, three of our leading API experts discuss these key challenges, what your company needs to succeed, and how partnering with a capable CDMO can make the biggest difference of all.
Featuring:
- Stephen Boppart, Director Business Management, API
- Matt Frizzle, Senior Business Manager, API
- Iain McGroarty, Senior Business Development Executive, API
access the Q&A!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Thermo Fisher Scientific
This website uses cookies to ensure you get the best experience on our website. Learn more